What question did this study set out to answer?

The research aims to develop E0714 as a selective Kv7.2 agonist for treating epilepsy while minimizing off-target effects.

February 21, 2026

View Full Paper

Discovery and Evaluation of E0714 as an Antiepileptic Candidate: A Highly Subtype-Selective Kv7 Agonist within the Kv7 Family Designed Based on a Kv7.2-Specific Pocket

Q: What does this research mean for the field?

E0714 selectively activates the Kv7.2 channel subtype by targeting specific residues (F112, Y118, and N289) and demonstrates potent antiepileptic effects without motor side effects in classical epilepsy models. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

KQKening QiaoHebei Medical University XLXiao LiuXihua University YCYawen CaoHebei Medical University

Key Result

E0714 selectively activates Kv7.2 channel subtype and showed potent antiepileptic effects without motor side effects in epilepsy models.

Key Points

The research aims to develop E0714 as a selective Kv7.2 agonist for treating epilepsy while minimizing off-target effects.
Identified specific Kv7.2 residues for selective binding using virtual screening.
Developed E0714 to activate Kv7.2 selectively during electrophysiology assays.
Conducted mechanistic studies to clarify E0714’s action at Kv7.2-specific residues.
E0714 potently activates Kv7.2 without affecting other Kv7 subtypes.
Demonstrated strong antiepileptic effects in traditional epilepsy models.
E0714 did not impair motor coordination, indicating a safer profile.

Structured PICO

Does E0714 provide antiepileptic effects without motor coordination problems in classical epilepsy models?

Population

Classical epilepsy models and in vitro Kv7 channels

Intervention

E0714 (a highly subtype-selective Kv7.2 agonist)

Outcome

Antiepileptic effect and subtype-selective activation of Kv7.2surrogate

E0714 is a highly selective Kv7.2 agonist that demonstrates antiepileptic efficacy in preclinical models without motor side effects, providing a framework for subtype-selective Kv7 drug design.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Subtype selectivity is critical in drug development, since off-target effects can restrict clinical application. Kv7.2 is a key target for treating neuronal hyperexcitability disorders. Nonselective activation of Kv7 channels can cause multisystem effects and increase therapeutic risk. Through a detailed analysis of Kv7 subtypes, we identified Kv7.2-specific residues to design a selective binding pocket. E0714 was then developed based on this pocket by virtual screening and compound modification. Electrophysiology assays demonstrated that E0714 potently activates Kv7.2 without significantly affecting Kv7.1, Kv7.3, Kv7.4, or Kv7.5. E0714 exhibited an excellent antiepileptic effect in classical epilepsy models without causing motor coordination problems. Mechanistic studies revealed that E0714 targets the Kv7.2-specific residues F112, Y118, and N289, which are responsible for the compound’s subtype-selective activation. These findings clarify the mechanism of action of E0714 and provide a framework for designing highly selective drugs against other Kv7 subtypes.

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

Qiao et al. (Thu,) reported a other. E0714 selectively activates Kv7.2 channel subtype and showed potent antiepileptic effects without motor side effects in epilepsy models.

synapsesocial.com/papers/69994c80873532290d020fc8 https://doi.org/https://doi.org/10.1021/acs.jmedchem.5c03052

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Perguntar à IA

Bookmark

View Full Paper